Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Cancer Genomics Proteomics. 2020 Jan-Feb;17(1):91-100. doi: 10.21873/cgp.20170.

Transcriptomic Analysis in Liquid Biopsy Identifies Circulating PCTAIRE-1 mRNA as a Biomarker in NSCLC.

Author information

1
Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan, R.O.C.
2
College of Medicine, Chang Gung University, Taoyuan, Taiwan, R.O.C.
3
Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan, R.O.C.
4
Department of Thoracic Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan, R.O.C.
5
Bioinformatics Resource Center, The Rockefeller University, New York, NY, U.S.A.
6
Department of Anatomic Pathology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, R.O.C.
7
Department of Cell and Molecular Biology, College of Medicine, Chang Gung University, Taoyuan, Taiwan, R.O.C.
8
Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan, R.O.C. ccchiou@mail.cgu.edu.tw.
9
Department of Medical Biotechnology and Laboratory Science, College of Medicine, Chang Gung University, Taoyuan, Taiwan, R.O.C.

Abstract

BACKGROUND/AIM:

Circulating mRNA can be a useful source of cancer biomarkers. We took advantage of direct transcriptomic analysis in plasma RNA to identify novel mRNA markers for non-small cell lung cancer (NSCLC).

PATIENTS AND METHODS:

Plasma RNA from NSCLC patients and healthy individuals was profiled with cDNA-mediated annealing, selection, extension and ligation (DASL) microarrays. The microarray results were further validated in plasma RNA.

RESULTS:

Through RNA profiling and online database mining, four gene transcripts were filtered as candidate markers of NSCLC. After validation, the PCTAIRE-1 transcript was identified as a circulating mRNA marker. The diagnostic potential of PCTAIRE-1 was evaluated by receiver operating characteristic curve analysis, which gave a sensitivity and specificity of 60% and 85%, respectively. In addition, high plasma PCTK1 levels were also correlated with poor progression-free survival (p=0.008).

CONCLUSION:

Circulating mRNA can be profiled with the DASL assay. From the profile, PCTAIRE-1 RNA in the plasma we discovered as a novel diagnostic/prognostic biomarker and an indicator of poor survival in NSCLC patients.

KEYWORDS:

PCTK1/CDK16; biomarker; circulating mRNA; non-small cell lung cancer

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central Icon for Rockefeller University Rita and Frits Markus Library
Loading ...
Support Center